Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

EDIT Editas Medicine Inc

-0.20 (-3.32%)
Last Updated: 12:00:14
Delayed by 15 minutes


Draw Mode:

Volume 753,117
Bid Price 5.81
Ask Price 5.82
News -
Day High 6.0512


52 Week Range


Day Low 5.655
Company Name Stock Ticker Symbol Market Type
Editas Medicine Inc EDIT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.20 -3.32% 5.82 12:00:14
Open Price Low Price High Price Close Price Prev Close
6.05 5.655 6.0512 6.02
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,284 753,117 $ 5.82 $ 4,382,842 - 4.91 - 11.91
Last Trade Time Type Quantity Stock Price Currency
12:00:14 127 $ 5.82 USD

Editas Medicine (EDIT) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Editas Medicine Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
475.34M 81.81M - 78.12M -153.22M -1.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Editas Medicine News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EDIT Message Board. Create One! See More Posts on EDIT Message Board See More Message Board Posts

Historical EDIT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.026.155.385.761,772,325-0.20-3.32%
1 Month5.276.694.915.551,901,3060.5510.44%
3 Months11.2911.384.916.921,933,086-5.47-48.45%
6 Months10.5311.694.918.201,887,888-4.71-44.73%
1 Year9.5211.914.918.361,832,881-3.70-38.87%
3 Years33.5573.0254.9117.661,774,628-27.73-82.65%
5 Years21.6599.954.9125.211,546,928-15.83-73.12%

Editas Medicine Description

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.

Your Recent History

Delayed Upgrade Clock